Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer

Tovi Shapira-Furman, Riccardo Serra, Noah Gorelick, Marisol Doglioli, Valentina Tagliaferri, Arba Cecia, Michael Peters, Awanish Kumar, Yakir Rottenberg, Robert Langer, Henry Brem, Betty Mae Tyler, Abraham J. Domb

Research output: Contribution to journalArticle

Abstract

Glioblastoma multiforme (GBM) has few clinically approved therapeutic regimens. One of these therapeutic options includes placing biodegradable wafers releasing BCNU (Gliadel®) into the tumor bed at the time of surgical removal of the tumor. Due to the significant benefit this polymer technology has had clinically, we have prepared wafers releasing Temozolomide (TMZ), an anticancer drug used systemically for treating GBM. TMZ delivered via polymer wafer could be used as a complementary treatment with or as an alternative to Gliadel®. TMZ is an alkylating agent which is water soluble. To remain comparable with the preclinical studies that led to Gliadel® the same size of wafers were formulated with TMZ. Wafers were loaded with 50% w/w TMZ in poly(lactic acid-glycolic acid) (PLGA) and showed reliable release of high dose TMZ for a period of 4 weeks. To achieve this 30-day release of the highly water soluble drug, we developed an encapsulation method, where the drug powder was first coated with the polymer to form core-shell particles in which the coating shell served as a rate controlling membrane for the drug particles. Wafers were also made with a co-loading of TMZ and BCNU. All wafers were tested in vivo by treating an intracranial 9 L gliosarcoma model in F344 rats. Rats that were either untreated or treated with blank wafer died within 11 days while the median survival for rats treated with systemic TMZ was 18 days. The group that received the BCNU alone wafer had a median survival of 15 days, the group that received the TMZ wafer alone had a median survival of 19 days, and the group treated with the BCNU-TMZ wafer had a median survival of 28 days with 25% of the animals living long term (p <.0038 vs. Control; p <.001 vs. Blank Polymer). These findings demonstrate the potential of this newly designed wafer for treating GBM. Moreover, this concept, can pave the way for other drug combinations that may improve the clinical application of numerous agents to treat solid tumors.

Original languageEnglish (US)
Pages (from-to)93-101
Number of pages9
JournalJournal of Controlled Release
Volume295
DOIs
StatePublished - Feb 10 2019

Fingerprint

temozolomide
Carmustine
Brain Neoplasms
Polymers
Glioblastoma
glycolic acid
Pharmaceutical Preparations
Gliosarcoma
Neoplasms
Water
Alkylating Agents

Keywords

  • BCNU
  • Brain tumor
  • GBM
  • Gliadel
  • PLGA
  • Temozolomide (TMZ)

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Shapira-Furman, T., Serra, R., Gorelick, N., Doglioli, M., Tagliaferri, V., Cecia, A., ... Domb, A. J. (2019). Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer. Journal of Controlled Release, 295, 93-101. https://doi.org/10.1016/j.jconrel.2018.12.048

Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer. / Shapira-Furman, Tovi; Serra, Riccardo; Gorelick, Noah; Doglioli, Marisol; Tagliaferri, Valentina; Cecia, Arba; Peters, Michael; Kumar, Awanish; Rottenberg, Yakir; Langer, Robert; Brem, Henry; Tyler, Betty Mae; Domb, Abraham J.

In: Journal of Controlled Release, Vol. 295, 10.02.2019, p. 93-101.

Research output: Contribution to journalArticle

Shapira-Furman, T, Serra, R, Gorelick, N, Doglioli, M, Tagliaferri, V, Cecia, A, Peters, M, Kumar, A, Rottenberg, Y, Langer, R, Brem, H, Tyler, BM & Domb, AJ 2019, 'Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer', Journal of Controlled Release, vol. 295, pp. 93-101. https://doi.org/10.1016/j.jconrel.2018.12.048
Shapira-Furman, Tovi ; Serra, Riccardo ; Gorelick, Noah ; Doglioli, Marisol ; Tagliaferri, Valentina ; Cecia, Arba ; Peters, Michael ; Kumar, Awanish ; Rottenberg, Yakir ; Langer, Robert ; Brem, Henry ; Tyler, Betty Mae ; Domb, Abraham J. / Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer. In: Journal of Controlled Release. 2019 ; Vol. 295. pp. 93-101.
@article{3cf57bdd7e304f7da515b764639d4bae,
title = "Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer",
abstract = "Glioblastoma multiforme (GBM) has few clinically approved therapeutic regimens. One of these therapeutic options includes placing biodegradable wafers releasing BCNU (Gliadel{\circledR}) into the tumor bed at the time of surgical removal of the tumor. Due to the significant benefit this polymer technology has had clinically, we have prepared wafers releasing Temozolomide (TMZ), an anticancer drug used systemically for treating GBM. TMZ delivered via polymer wafer could be used as a complementary treatment with or as an alternative to Gliadel{\circledR}. TMZ is an alkylating agent which is water soluble. To remain comparable with the preclinical studies that led to Gliadel{\circledR} the same size of wafers were formulated with TMZ. Wafers were loaded with 50{\%} w/w TMZ in poly(lactic acid-glycolic acid) (PLGA) and showed reliable release of high dose TMZ for a period of 4 weeks. To achieve this 30-day release of the highly water soluble drug, we developed an encapsulation method, where the drug powder was first coated with the polymer to form core-shell particles in which the coating shell served as a rate controlling membrane for the drug particles. Wafers were also made with a co-loading of TMZ and BCNU. All wafers were tested in vivo by treating an intracranial 9 L gliosarcoma model in F344 rats. Rats that were either untreated or treated with blank wafer died within 11 days while the median survival for rats treated with systemic TMZ was 18 days. The group that received the BCNU alone wafer had a median survival of 15 days, the group that received the TMZ wafer alone had a median survival of 19 days, and the group treated with the BCNU-TMZ wafer had a median survival of 28 days with 25{\%} of the animals living long term (p <.0038 vs. Control; p <.001 vs. Blank Polymer). These findings demonstrate the potential of this newly designed wafer for treating GBM. Moreover, this concept, can pave the way for other drug combinations that may improve the clinical application of numerous agents to treat solid tumors.",
keywords = "BCNU, Brain tumor, GBM, Gliadel, PLGA, Temozolomide (TMZ)",
author = "Tovi Shapira-Furman and Riccardo Serra and Noah Gorelick and Marisol Doglioli and Valentina Tagliaferri and Arba Cecia and Michael Peters and Awanish Kumar and Yakir Rottenberg and Robert Langer and Henry Brem and Tyler, {Betty Mae} and Domb, {Abraham J.}",
year = "2019",
month = "2",
day = "10",
doi = "10.1016/j.jconrel.2018.12.048",
language = "English (US)",
volume = "295",
pages = "93--101",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer

AU - Shapira-Furman, Tovi

AU - Serra, Riccardo

AU - Gorelick, Noah

AU - Doglioli, Marisol

AU - Tagliaferri, Valentina

AU - Cecia, Arba

AU - Peters, Michael

AU - Kumar, Awanish

AU - Rottenberg, Yakir

AU - Langer, Robert

AU - Brem, Henry

AU - Tyler, Betty Mae

AU - Domb, Abraham J.

PY - 2019/2/10

Y1 - 2019/2/10

N2 - Glioblastoma multiforme (GBM) has few clinically approved therapeutic regimens. One of these therapeutic options includes placing biodegradable wafers releasing BCNU (Gliadel®) into the tumor bed at the time of surgical removal of the tumor. Due to the significant benefit this polymer technology has had clinically, we have prepared wafers releasing Temozolomide (TMZ), an anticancer drug used systemically for treating GBM. TMZ delivered via polymer wafer could be used as a complementary treatment with or as an alternative to Gliadel®. TMZ is an alkylating agent which is water soluble. To remain comparable with the preclinical studies that led to Gliadel® the same size of wafers were formulated with TMZ. Wafers were loaded with 50% w/w TMZ in poly(lactic acid-glycolic acid) (PLGA) and showed reliable release of high dose TMZ for a period of 4 weeks. To achieve this 30-day release of the highly water soluble drug, we developed an encapsulation method, where the drug powder was first coated with the polymer to form core-shell particles in which the coating shell served as a rate controlling membrane for the drug particles. Wafers were also made with a co-loading of TMZ and BCNU. All wafers were tested in vivo by treating an intracranial 9 L gliosarcoma model in F344 rats. Rats that were either untreated or treated with blank wafer died within 11 days while the median survival for rats treated with systemic TMZ was 18 days. The group that received the BCNU alone wafer had a median survival of 15 days, the group that received the TMZ wafer alone had a median survival of 19 days, and the group treated with the BCNU-TMZ wafer had a median survival of 28 days with 25% of the animals living long term (p <.0038 vs. Control; p <.001 vs. Blank Polymer). These findings demonstrate the potential of this newly designed wafer for treating GBM. Moreover, this concept, can pave the way for other drug combinations that may improve the clinical application of numerous agents to treat solid tumors.

AB - Glioblastoma multiforme (GBM) has few clinically approved therapeutic regimens. One of these therapeutic options includes placing biodegradable wafers releasing BCNU (Gliadel®) into the tumor bed at the time of surgical removal of the tumor. Due to the significant benefit this polymer technology has had clinically, we have prepared wafers releasing Temozolomide (TMZ), an anticancer drug used systemically for treating GBM. TMZ delivered via polymer wafer could be used as a complementary treatment with or as an alternative to Gliadel®. TMZ is an alkylating agent which is water soluble. To remain comparable with the preclinical studies that led to Gliadel® the same size of wafers were formulated with TMZ. Wafers were loaded with 50% w/w TMZ in poly(lactic acid-glycolic acid) (PLGA) and showed reliable release of high dose TMZ for a period of 4 weeks. To achieve this 30-day release of the highly water soluble drug, we developed an encapsulation method, where the drug powder was first coated with the polymer to form core-shell particles in which the coating shell served as a rate controlling membrane for the drug particles. Wafers were also made with a co-loading of TMZ and BCNU. All wafers were tested in vivo by treating an intracranial 9 L gliosarcoma model in F344 rats. Rats that were either untreated or treated with blank wafer died within 11 days while the median survival for rats treated with systemic TMZ was 18 days. The group that received the BCNU alone wafer had a median survival of 15 days, the group that received the TMZ wafer alone had a median survival of 19 days, and the group treated with the BCNU-TMZ wafer had a median survival of 28 days with 25% of the animals living long term (p <.0038 vs. Control; p <.001 vs. Blank Polymer). These findings demonstrate the potential of this newly designed wafer for treating GBM. Moreover, this concept, can pave the way for other drug combinations that may improve the clinical application of numerous agents to treat solid tumors.

KW - BCNU

KW - Brain tumor

KW - GBM

KW - Gliadel

KW - PLGA

KW - Temozolomide (TMZ)

UR - http://www.scopus.com/inward/record.url?scp=85059349054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059349054&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2018.12.048

DO - 10.1016/j.jconrel.2018.12.048

M3 - Article

C2 - 30605703

AN - SCOPUS:85059349054

VL - 295

SP - 93

EP - 101

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -